<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Fox, Kim</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">BEAUTIFUL Trial Fails to Meet Primary Endpoint</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">Although the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary artery disease and left ventricULar dysfunction [BEAUTIFUL; NCT00143507] trial failed to meet its primary composite endpoint of cardiovascular death, admission to hospital for acute myocardial infarction (MI), and hospitalization for new-onset or worsening heart failure, it significantly reduced important secondary endpoints, such as hospitalization for fatal or non-fatal MI and coronary revascularization.</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>